Overview

Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes

Status:
Enrolling by invitation

Trial end date:
2022-04-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to switch from insulin to oral sulfonylurea in patients with apparent type 1 diabetes or maturity onset diabetes in the young that are insulin treated. The molecular cause will be DNA variants in the HNF1A, HNF4A, or HNF1B genes that are of unknown significance (VUS, class 3) or known to be pathogenic (class 4 and 5).

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Haukeland University Hospital

Treatments:

Glipizide
Glyburide
Insulin

Criteria

Inclusion Criteria:

- Diabetes and DNA sequence variant of unknown significance (VUS, class 3) or pathogenic
(class 4, and 5) in the HNF1A, HNF4A, or HNF1B genes

- On insulin treatment

- Willing and able to provide informed consent (parents if younger than 16 years of age)

Exclusion Criteria:

- Known anaphylactic response to sulfonylurea

- Diabetes and DNA sequence variant in the HNF1A, HNF4A, or HNF1B genes that are known
to be non-pathogenic (class 1-2)

- Not willing or able to provide informed consent (parents if younger than 16 years of
age)